|
EVIDENCE
WATCH
A review and assessment of recent
clinical trial data
Contributors were selected by Joseph Ragaz, MD,
FRCPC, McGill University, Montreal, QC.
To view the clinical trial data of the
following topics click
here (pdf format)
Hormonal
therapy in early postmenopausal breast cancer
Debjani Grenier, MD, FRCPC, Medical
Oncologist, CancerCare Manitoba, St. Boniface General Hospital,
Winnipeg, MB.
Jones SE, Seynaeve C, Hasenburg A et
al. Results of the first planned analysis of the TEAM (tamoxifen
exemestane adjuvant multinational) prospective randomized
phase III trial in hormone sensitive postmenopausal early
breast cancer. SABCS 2008, Abstract 15.
Zoledronic
acid and bone loss in women receiving letrozole
Sunil
Verma, MD, MSEd, FRCPC, Medical Oncologist, Odette Cancer
Centre, and Danny Robson, MD, FRCPC, Breast Oncology Fellow,
Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto,
ON.
H. Eidtmann
et al. The effect of zoledronic acid on aromatase inhibitor
associated bone loss in postmenopausal women with early breast
cancer receiving adjuvant letrozole: 36 months follow-up of
ZO-FAST. SABCS 2008, Abstract 44.
Lapatinib
added to endocrine therapy in metastatic breast cancer
Sunil
Verma, MD, MSEd, FRCPC, Medical Oncologist, Odette Cancer
Centre, and Danny Robson, MD, FRCPC, Breast Oncology Fellow,
Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto,
ON.
S. Johnston
et al. Lapatinib combined with letrozole vs. letrozole alone
for front line postmenopausal hormone receptor positive (HR+)
metastatic breast cancer (MBC): first results from the EGF30008
Trial. SABCS 2008, Abstract 46.
Using
breast density to predict tamoxifen efficacy in breast cancer
prevention
Joseph
Ragaz, MD, FRCPC, Medical Oncologist; Clinical Professor and
Senior Oncology Researcher, McGill University, Montreal, QC.
Cuzick
J, Warwick J, Pinney L et al. et al. Change in breast density
as a biomarker of breast cancer risk reduction; results from
IBIS-I. SABCS 2008, Abstract 61.
|
